| scholarly article | Q13442814 |
| P50 | author | Jesús Madero Pérez | Q64681991 |
| Sabine Hilfiker | Q37379397 | ||
| P2093 | author name string | Belén Fernández | |
| Pilar Rivero-Ríos | |||
| P2860 | cites work | α-Synuclein Is Degraded by Both Autophagy and the Proteasome | Q44420467 |
| Rab7 is required for the normal progression of the autophagic pathway in mammalian cells | Q44892471 | ||
| Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. | Q45303665 | ||
| Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. | Q45923687 | ||
| Temporal analysis of recruitment of mammalian ATG proteins to the autophagosome formation site. | Q45968828 | ||
| Neuronal autophagy, α-synuclein clearance, and LRRK2 regulation: a lost equilibrium in parkinsonian brain. | Q48320011 | ||
| Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons | Q48588748 | ||
| LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity. | Q48627154 | ||
| Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. | Q48806014 | ||
| Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration | Q50479107 | ||
| Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. | Q21135493 | ||
| PINK1 is selectively stabilized on impaired mitochondria to activate Parkin | Q21145802 | ||
| Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP | Q24293723 | ||
| Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease | Q24294458 | ||
| Ubiquitin is phosphorylated by PINK1 to activate parkin | Q24296532 | ||
| Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies | Q24307627 | ||
| RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk | Q24315688 | ||
| Parkin is recruited selectively to impaired mitochondria and promotes their autophagy | Q24317471 | ||
| The familial Parkinsonism gene LRRK2 regulates neurite process morphology | Q24317613 | ||
| Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies | Q24318474 | ||
| Interplay of LRRK2 with chaperone-mediated autophagy | Q24322747 | ||
| Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brain | Q24599233 | ||
| Chaperone-mediated autophagy: a unique way to enter the lysosome world | Q24628159 | ||
| Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro | Q24629968 | ||
| A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease | Q24633417 | ||
| mTOR signaling in growth control and disease | Q24634174 | ||
| Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection | Q24650675 | ||
| Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells | Q24651391 | ||
| LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model | Q24656256 | ||
| Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy | Q24683089 | ||
| Definition of a molecular pathway mediating α-synuclein neurotoxicity | Q26269832 | ||
| Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities | Q26269871 | ||
| Receptor-mediated mitophagy in yeast and mammalian systems | Q26821921 | ||
| PINK1 and Parkin – mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease | Q26866451 | ||
| Glucocerebrosidase and Parkinson disease: Recent advances | Q27005669 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| Autophagy fights disease through cellular self-digestion | Q27860902 | ||
| Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase | Q28116395 | ||
| Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein | Q28117589 | ||
| Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice | Q28131756 | ||
| Loss of autophagy in the central nervous system causes neurodegeneration in mice | Q28131804 | ||
| Adapting proteostasis for disease intervention | Q28131818 | ||
| Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice | Q28507051 | ||
| Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain | Q28509158 | ||
| Identification of a candidate therapeutic autophagy-inducing peptide | Q28593490 | ||
| DNAJC13 mutations in Parkinson disease | Q28658355 | ||
| SNARE proteins are required for macroautophagy | Q28742152 | ||
| Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy | Q29614178 | ||
| TFEB links autophagy to lysosomal biogenesis | Q29614835 | ||
| PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity | Q29617292 | ||
| Eaten alive: a history of macroautophagy | Q29617841 | ||
| High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease | Q29619113 | ||
| Role for Rab7 in maturation of late autophagic vacuoles | Q30014819 | ||
| Autophagosome biogenesis in primary neurons follows an ordered and spatially regulated pathway | Q30584888 | ||
| GTPase activity plays a key role in the pathobiology of LRRK2. | Q33553458 | ||
| Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases | Q33613123 | ||
| Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy | Q33670282 | ||
| Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy | Q33920691 | ||
| The link between the GBA gene and parkinsonism | Q34077492 | ||
| Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome | Q34600785 | ||
| Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity | Q34636872 | ||
| The many faces of α-synuclein: from structure and toxicity to therapeutic target | Q34972009 | ||
| Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. | Q34995420 | ||
| α-Synuclein impairs macroautophagy: implications for Parkinson's disease. | Q35005567 | ||
| VPS35 mutations in Parkinson disease | Q35103751 | ||
| Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies | Q35152946 | ||
| α-Synuclein fate is determined by USP9X-regulated monoubiquitination | Q35558701 | ||
| Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease | Q35686212 | ||
| Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway | Q35811884 | ||
| Trehalose transporter 1, a facilitated and high-capacity trehalose transporter, allows exogenous trehalose uptake into cells | Q35867649 | ||
| Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. | Q36066469 | ||
| ER stress inhibits neuronal death by promoting autophagy | Q36187772 | ||
| Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain | Q36469322 | ||
| Uptake--microautophagy--and degradation of exogenous proteins by isolated rat liver lysosomes. Effects of pH, ATP, and inhibitors of proteolysis | Q36493529 | ||
| The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease | Q36611426 | ||
| Constitutive activation of chaperone-mediated autophagy in cells with impaired macroautophagy | Q36631143 | ||
| Distinct RolesIn Vivofor the Ubiquitin–Proteasome System and the Autophagy–Lysosomal Pathway in the Degradation of α-Synuclein | Q36653589 | ||
| Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α-synuclein accumulation and age-dependent sensorimotor deficits | Q36787223 | ||
| TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity | Q36835587 | ||
| Lewy Body-like α-Synuclein Aggregates Resist Degradation and Impair Macroautophagy | Q36873680 | ||
| Mitochondria in the aetiology and pathogenesis of Parkinson's disease | Q37037953 | ||
| Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein | Q37278480 | ||
| Chemical modulators of autophagy as biological probes and potential therapeutics | Q37821750 | ||
| Pharmacological chaperone therapy for Gaucher disease: a patent review. | Q37860332 | ||
| The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim? | Q37978123 | ||
| The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders | Q38012653 | ||
| Lysosome-dependent pathways as a unifying theme in Parkinson's disease. | Q38038561 | ||
| Dysfunction of the autophagy/lysosomal degradation pathway is a shared feature of the genetic synucleinopathies | Q38107478 | ||
| Advances in the genetics of Parkinson disease | Q38121773 | ||
| Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease. | Q38215066 | ||
| Targeting autophagy in neurodegenerative diseases | Q38255732 | ||
| Selective removal of mitochondria via mitophagy: distinct pathways for different mitochondrial stresses. | Q38404165 | ||
| LRRK2 Pathways Leading to Neurodegeneration | Q38501861 | ||
| The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer | Q39072935 | ||
| Phosphorylated ubiquitin chain is the genuine Parkin receptor. | Q39589823 | ||
| Pathogenic lysosomal depletion in Parkinson's disease | Q39655523 | ||
| Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease | Q40887263 | ||
| Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. | Q41964090 | ||
| Novel targets for Huntington's disease in an mTOR-independent autophagy pathway | Q41978909 | ||
| Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells | Q42423397 | ||
| Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation | Q42472879 | ||
| The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway | Q42509261 | ||
| Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model | Q42704695 | ||
| Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons | Q44193974 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autophagy | Q288322 |
| cell | Q7868 | ||
| Parkinson's disease | Q11085 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 238-249 | |
| P577 | publication date | 2016-01-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Current Neuropharmacology | Q20181354 |
| P1476 | title | Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson's Disease | |
| P478 | volume | 14 |
| Q96304526 | "LRRK2: Autophagy and Lysosomal Activity" |
| Q59133878 | Ageing, Cellular Senescence and Neurodegenerative Disease |
| Q28079911 | Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application |
| Q91606782 | Astragaloside IV inhibits astrocyte senescence: implication in Parkinson's disease |
| Q64763405 | Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery |
| Q89963829 | Cellular Senescence in Neurodegenerative Diseases |
| Q64231716 | Killing Two Angry Birds with One Stone: Autophagy Activation by Inhibiting Calpains in Neurodegenerative Diseases and Beyond |
| Q28078899 | LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives |
| Q47222125 | New Insights into the Potential Roles of 3-Iodothyronamine (T1AM) and Newly Developed Thyronamine-Like TAAR1 Agonists in Neuroprotection |
| Q64272978 | Novel Approaches for the Treatment of Alzheimer's and Parkinson's Disease |
| Q41116590 | Role of mammalian target of rapamycin signaling in autophagy and the neurodegenerative process using a senescence accelerated mouse-prone 8 model |
| Q33703425 | Two-Pore Channels and Parkinson's Disease: Where's the Link? |
Search more.